Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Aug;71(8):6044–6048. doi: 10.1128/jvi.71.8.6044-6048.1997

Both T and B cells shed infectious mouse mammary tumor virus.

J L Dzuris 1, T V Golovkina 1, S R Ross 1
PMCID: PMC191862  PMID: 9223496

Abstract

Mouse mammary tumor virus (MMTV) infected both B and T tissue culture cells and primary B and T cells in vivo after milk-borne transmission of the virus. The infected tissue culture cells processed viral proteins, and both these and primary B and T cells shed virus when cultured in vitro. Moreover, the infected B and T tissue culture cells transmitted virus to uninfected mammary gland cells in vitro. The level of infection of these different cell types in vivo was dependent on the strain of mouse, with C3H/HeN mice showing greater B-cell infection and BALB/c mice greater T-cell infection after nursing on MMTV-infected C3H/HeN mothers. Although their B cells were less infected, BALB/c mice developed tumors more rapidly than C3H/HeN mice. These results indicate that both infected T and B cells are potential carriers of MMTV in vivo.

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acha-Orbea H., MacDonald H. R. Superantigens of mouse mammary tumor virus. Annu Rev Immunol. 1995;13:459–486. doi: 10.1146/annurev.iy.13.040195.002331. [DOI] [PubMed] [Google Scholar]
  2. Beutner U., Kraus E., Kitamura D., Rajewsky K., Huber B. T. B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens. J Exp Med. 1994 May 1;179(5):1457–1466. doi: 10.1084/jem.179.5.1457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  4. Desaymard C., Tucek C. L., Rocha B., Korman A. J., Papiernik M. Tissue distribution of Mtv-7-like exogenous retroviral transcripts and clonal deletion of V beta 6+ T cells in Mls-1b BALB/c mice. Int Immunol. 1993 Feb;5(2):217–222. doi: 10.1093/intimm/5.2.217. [DOI] [PubMed] [Google Scholar]
  5. Golovkina T. V., Chervonsky A., Dudley J. P., Ross S. R. Transgenic mouse mammary tumor virus superantigen expression prevents viral infection. Cell. 1992 May 15;69(4):637–645. doi: 10.1016/0092-8674(92)90227-4. [DOI] [PubMed] [Google Scholar]
  6. Golovkina T. V., Chervonsky A., Prescott J. A., Janeway C. A., Jr, Ross S. R. The mouse mammary tumor virus envelope gene product is required for superantigen presentation to T cells. J Exp Med. 1994 Feb 1;179(2):439–446. doi: 10.1084/jem.179.2.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Golovkina T. V., Dudley J. P., Jaffe A. B., Ross S. R. Mouse mammary tumor viruses with functional superantigen genes are selected during in vivo infection. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4828–4832. doi: 10.1073/pnas.92.11.4828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Golovkina T. V., Jaffe A. B., Ross S. R. Coexpression of exogenous and endogenous mouse mammary tumor virus RNA in vivo results in viral recombination and broadens the virus host range. J Virol. 1994 Aug;68(8):5019–5026. doi: 10.1128/jvi.68.8.5019-5026.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Golovkina T. V., Piazzon I., Nepomnaschy I., Buggiano V., de Olano Vela M., Ross S. R. Generation of a tumorigenic milk-borne mouse mammary tumor virus by recombination between endogenous and exogenous viruses. J Virol. 1997 May;71(5):3895–3903. doi: 10.1128/jvi.71.5.3895-3903.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Held W., Shakhov A. N., Izui S., Waanders G. A., Scarpellino L., MacDonald H. R., Acha-Orbea H. Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus. J Exp Med. 1993 Feb 1;177(2):359–366. doi: 10.1084/jem.177.2.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Held W., Waanders G. A., Acha-Orbea H., MacDonald H. R. Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med. 1994 Dec 1;180(6):2347–2351. doi: 10.1084/jem.180.6.2347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Held W., Waanders G. A., Shakhov A. N., Scarpellino L., Acha-Orbea H., MacDonald H. R. Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell. 1993 Aug 13;74(3):529–540. doi: 10.1016/0092-8674(93)80054-i. [DOI] [PubMed] [Google Scholar]
  13. Ignatowicz L., Kappler J., Marrack P. The effects of chronic infection with a superantigen-producing virus. J Exp Med. 1992 Apr 1;175(4):917–923. doi: 10.1084/jem.175.4.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karapetian O., Shakhov A. N., Kraehenbuhl J. P., Acha-Orbea H. Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model. J Exp Med. 1994 Oct 1;180(4):1511–1516. doi: 10.1084/jem.180.4.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nusse R., van der Ploeg L., van Duijn L., Michalides R., Hilgers J. Impaired maturation of mouse mammary tumor virus precursor polypeptides in lymphoid leukemia cells, producing intracytoplasmic A particles and no extracellular B-type virions. J Virol. 1979 Oct;32(1):251–258. doi: 10.1128/jvi.32.1.251-258.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Scherer M. T., Ignatowicz L., Winslow G. M., Kappler J. W., Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu Rev Cell Biol. 1993;9:101–128. doi: 10.1146/annurev.cb.09.110193.000533. [DOI] [PubMed] [Google Scholar]
  17. Schochetman G., Arthur L. O., Long C. W., Massey R. J. Mice with spontaneous mammary tumors develop type-specific neutralizing and cytotoxic antibodies against the mouse mammary tumor virus envelope protein gp52. J Virol. 1979 Oct;32(1):131–139. doi: 10.1128/jvi.32.1.131-139.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Shackleford G. M., Varmus H. E. Construction of a clonable, infectious, and tumorigenic mouse mammary tumor virus provirus and a derivative genetic vector. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9655–9659. doi: 10.1073/pnas.85.24.9655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tsubura A., Inaba M., Imai S., Murakami A., Oyaizu N., Yasumizu R., Ohnishi Y., Tanaka H., Morii S., Ikehara S. Intervention of T-cells in transportation of mouse mammary tumor virus (milk factor) to mammary gland cells in vivo. Cancer Res. 1988 Nov 15;48(22):6555–6559. [PubMed] [Google Scholar]
  20. Waanders G. A., Shakhov A. N., Held W., Karapetian O., Acha-Orbea H., MacDonald H. R. Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus. J Exp Med. 1993 May 1;177(5):1359–1366. doi: 10.1084/jem.177.5.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES